GLP-1 Dose Response: Titration, Plateaus, Missed Doses, and Microdosing Explained

Does a higher GLP-1 dose mean more weight loss?

Usually yes, within the doses that were tested. In SURMOUNT-1, 2,539 adults with obesity or overweight and no diabetes were assigned to tirzepatide 5, 10 or 15 mg once weekly or placebo for 72 weeks, including a 20-week dose-escalation period. Mean weight change at 72 weeks (treatment-regimen estimand) was -15.0%, -19.5% and -20.9% with tirzepatide 5, 10 and 15 mg, respectively, versus -3.1% with placebo [2].

The size of each step is not equal. Going from 5 mg to 10 mg moved the average from -15.0% to -19.5%, an extra 4.5 points of loss; going from 10 mg to 15 mg moved it from -19.5% to -20.9%, an extra 1.4 points [2]. The same flattening shows in the glycemic data: in SURPASS-2, 1,879 adults with type 2 diabetes on tirzepatide 5, 10 or 15 mg lowered HbA1c by 2.01, 2.24 and 2.30 points over 40 weeks, against 1.86 points on semaglutide 1 mg [5].

Semaglutide's diabetes doses also show a higher-dose, larger-effect pattern. In SUSTAIN 7, 1,201 adults with type 2 diabetes took semaglutide 0.5 mg or 1 mg once weekly for 40 weeks; HbA1c fell 1.5 and 1.8 points and body weight fell 4.6 and 6.5 kg [7].

Populations differ, so these results cannot isolate the effect of dose alone. The 2.4 mg dose produced 14.9% weight loss in STEP 1, which excluded people with diabetes [3], and 9.6% in STEP 2, which enrolled 1,210 adults with type 2 diabetes, against 3.4% on placebo [8].

Why every product starts low and steps up

Labels build the escalation into the dosing instructions to reduce the risk of gastrointestinal side effects. In the pooled Foundayo trials, nausea, vomiting and diarrhea were more frequent during the escalation period and decreased over time [1]. Among adults taking Wegovy 2.4 mg for up to 68 weeks, 6.8% stopped the drug because of adverse reactions, against 3.2% on placebo, with nausea the most common reason (1.8% versus 0.2%) [4].

The labeled paths differ by product and form.

• Wegovy injection: the label starts at 0.25 mg once weekly for 4 weeks, then titrates every 4 weeks to the maintenance dose. The usual maintenance dose is 2.4 mg once weekly. If 2.4 mg is not tolerated, the label says the dose can be decreased to 1.7 mg, and re-escalation to 2.4 mg can be considered [4].
• Wegovy tablets: the label starts at 1.5 mg once daily for 30 days, then titrates every 30 days; the recommended maintenance dose is 25 mg once daily [4].
• Foundayo (orforglipron) tablets: the label starts at 0.8 mg once daily. After at least 30 days it moves to 2.5 mg, and after at least another 30 days to 5.5 mg. Further increases to 9, 14.5 or 17.2 mg follow after at least 30 days on the current dose, based on treatment response and tolerability. The maximum dose is 17.2 mg once daily [1].

Gastrointestinal effects are common at maintenance doses. Nausea was reported by 44% of adults on Wegovy 2.4 mg versus 16% on placebo, vomiting by 24% versus 6%, diarrhea by 30% versus 16% and constipation by 24% versus 11% [4]. In pooled Foundayo trials, gastrointestinal adverse reactions occurred in 60%, 68% and 69% of adults on 5.5, 9 and 17.2 mg respectively, against 37% on placebo [1].

How fast can the dose go up?

The labels set a minimum time on each dose, and it differs by product. Wegovy injection is titrated every 4 weeks [4]. Foundayo allows a step after at least 30 days on the current dose, and later steps depend on treatment response and tolerability [1].

Missed doses

For Foundayo, the label says a missed dose should be taken as soon as possible, without doubling up the next dose. After 7 or more consecutive missed doses, the label says to restart dosage escalation at a lower dose to reduce the risk of gastrointestinal adverse reactions [1].

For Wegovy injection, the label says the dose is given once weekly, on the same day each week, at any time of day, with or without meals, into the abdomen, thigh or upper arm, and that the time of day and the injection site can be changed without a dosage modification [4].

Weight loss plateaus and dose changes

The trials cited on this page tested set doses or maximum tolerated doses, not a protocol for a plateau. In SURMOUNT-5, 751 adults with obesity but no diabetes received the maximum tolerated dose of tirzepatide (10 or 15 mg) or of semaglutide (1.7 or 2.4 mg) for 72 weeks. Weight fell 20.2% with tirzepatide and 13.7% with semaglutide, and waist circumference fell 18.4 cm and 13.0 cm [9].

In SURMOUNT-3, 579 adults first completed a 12-week intensive lifestyle intervention and lost at least 5% of body weight; they were then randomized to tirzepatide (10 or 15 mg) or placebo for 72 weeks. From randomization, the tirzepatide group lost an additional 18.4% while the placebo group gained 2.5% [10].

Weight also depends on staying on treatment. In STEP 4, 803 adults who had reached 2.4 mg weekly were randomized to continue semaglutide or switch to placebo for 48 weeks; the continued group lost another 7.9% of body weight while the placebo group gained 6.9% [6].

What about microdosing?

Microdosing means starting below the labeled starting dose. The labeled starting doses are 0.25 mg weekly for Wegovy injection, 1.5 mg daily for Wegovy tablets, and 0.8 mg daily for Foundayo [4][1]. The weight-loss results above come from labeled doses and trial dose arms, not from fractions of them.

All current US GLP-1 products are prescription-only, as injections or tablets, and none is sold over the counter [4][1]. Compounded semaglutide and tirzepatide are not FDA approved, and FDA has received adverse-event reports involving both products, including reports of dosing errors [11][12].